Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-506 in Rheumatoid Arthritis
NCT04204603Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of CKD-506 in rheumatoid arthritis (RA) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Change from baseline in Disease Activity Score 28-joint count using C-reactive protein at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
CKD-506
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04204603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204603.